Skip to main content

Advertisement

SpringerLink
Log in

Authors’ reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 13 March 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Evangelista L, Alongi P. PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer? Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05295-2.

  2. Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05210-9.

  3. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. https://doi.org/10.1007/s00259-012-2298-2.

    Article  CAS  Google Scholar 

  4. Alberts I, Sachpekidis C, Fech V, Rominger A, Afshar-Oromieh A. PSMA-negative prostate cancer and the continued value of choline-PET/CT. Nuklearmedizin Nucl Med. 2020;59:1. https://doi.org/10.1055/a-1044-1855.

    Article  Google Scholar 

  5. Iravani A, Mitchell C, Akhurst T, Sandhu S, Hofman MS, Hicks RJ. Molecular imaging of neuroendocrine differentiation of prostate cancer: a case series. Clin Genitourin Cancer. 2021. https://doi.org/10.1016/j.clgc.2021.01.008.

  6. Michalski K, Ruf J, Goetz C, Seitz AK, Buck AK, Lapa C, et al. Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05160-8.

  7. Khreish F, Rosar F, Kratochwil C, Giesel FL, Haberkorn U, Ezziddin S. Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. Eur J Nucl Med Mol Imaging. 2020;47:2040–1. https://doi.org/10.1007/s00259-019-04623-x.

    Article  Google Scholar 

  8. Alberts I, Prenosil G, Sachpekidis C, Weitzel T, Shi K, Rominger A, et al. Digital versus analogue PET in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2020;47:614–23. https://doi.org/10.1007/s00259-019-04630-y.

    Article  CAS  PubMed  Google Scholar 

  9. Alberts I, Hünermund J-N, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05282-7.

  10. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–94. https://doi.org/10.1016/S1470-2045(19)30415-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–5.

    CAS  PubMed  Google Scholar 

  12. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014;9:e99682. https://doi.org/10.1371/journal.pone.0099682.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland

    Ian Alberts, Clemens Mingels, Karl Peter Bohn, Kuangyu Shi, Axel Rominger & Ali Afshar-Oromieh

  2. Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany

    Svenja Elizabeth Seide

  3. Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18-22, DK-9000, Aalborg, Denmark

    Helle D Zacho

Authors
  1. Ian Alberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Svenja Elizabeth Seide
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clemens Mingels
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karl Peter Bohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kuangyu Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Helle D Zacho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Axel Rominger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ali Afshar-Oromieh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian Alberts.

Ethics declarations

Ethical approval

This response does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

This article is part of the Topical Collection on Letter to the Editor

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alberts, I., Seide, S.E., Mingels, C. et al. Authors’ reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. Eur J Nucl Med Mol Imaging 48, 2307–2308 (2021). https://doi.org/10.1007/s00259-021-05376-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-021-05376-2

Search

Navigation